Old Web
English
Sign In
Acemap
>
Paper
>
The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?
The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?
2018
Shamir Geller
Patricia L. Myskowski
Youn H. Kim
Alison J. Moskowitz
S. Horwitz
Keywords:
Dermatology
CD30
Regimen
Pathology
Brentuximab vedotin
Cutaneous lymphoma
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
3
References
4
Citations
NaN
KQI
[]